Compare Cintas Corporation (CTAS) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs DexCom, Inc. — how do they compare? Cintas Corporation trades at $203.87 (market cap $82.15B), while DexCom, Inc. trades at $89.03 (market cap $33.79B). The key difference: Cintas Corporation is far larger — about 2.4× DexCom, Inc.'s market cap, and Cintas Corporation pays a 1.01% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| CTAS | DXCM | |
|---|---|---|
Market Cap | $82.15B | $33.79B |
Sector | Industrials | Health |
52-Week High | $225.10 | $89.53 |
52-Week Low | $163.55 | $54.84 |
Enterprise Value | $84.56B | $33.24B |
Dividend Yield | 1.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTAS trades at $203.06, showing modest daily gains. The stock exhibits a bullish technical trend, supported by recent earnings beats and strong profitability metrics, including a 17.75% net income margin. Recent news highlights dividend declarations and positive analyst upgrades following Q4 2026 results.
The outlook is positive, with revenue growth and margin expansion driving upside potential toward the $225.83 consensus price target. Risks include elevated valuation multiples and macroeconomic sensitivity. Institutional activity shows mixed positioning, but overall sentiment leans bullish.
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
